spacer
home > ebr > summer 2003 > cold chain: risk, regulatory compliance and operational performance
PUBLICATIONS
European Biopharmaceutical Review

Cold Chain: Risk, Regulatory Compliance and Operational Performance

Risk assessment is, at best, an honest attempt to find a rational basis for decisions by analysing the available scientific evidence. In theory it is still an attractive ideal - to make rational decisions based on scientific evidence - because in principle it should allow diverse parties to agree on what needs to be done. However, years of actual practice have badly tarnished the ideal of risk assessment.

In the first place, the necessary data are not always available, even today. In the second place, the traditional toxicological assumptions do not always hold up under scrutiny. There is no agreement on which tests to use to determine whether someone's immune system has been damaged. There is no agreement on which tests should be used to assess damage to the nervous system. There is no agreement - and there may never be - on ways to test for genetic damage.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sean Flanagan, the Commercial Director at Kryotrans Ltd, and Adrian Shaw, Partner at Ikon Associates

Sean Flanagan is the Commercial Director at Kryotrans Ltd. A qualified accountant, Sean has considerable financial and operational experience with a range of large and small organisations, such as United Technologies Corporation and PROTX Ltd, an Internet start-up company.

He is one of three directors at Kryotrans Ltd. He is responsible for marketing, finance, sales and administration and has also developed a number of strategic partnering relationships.


Adrian Shaw is a Partner at Ikon Associates, Marketing Consultants. Having trained in accountancy with Coopers and Lybrand, Adrian has spent the last 15 years working in the PR and marketing services world.

He has previously worked as a Director for Gavin Anderson & Co, a PR consultancy, before moving on to Burston Marsteller, where he was a Managing Director responsible for financial and corporate communications work across Europe. He now runs his own corporate brand and marketing services consultancy.


spacer
Sean Flanagan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement